{"retracted":false,"update":{"timestamp":1406764800000,"doi":"10.1371/journal.pone.0105179","type":"correction"},"doi":"10.1371/journal.pone.0096316","journal":"PLoS ONE","publisher":"Public Library of Science (PLoS)","title":"Correction: Continuing a cancer treatment despite tumor growth may be valuable: Sunitinib in renal cell carcinoma as example"}
